TerminatedEarly Phase 1NCT05316116
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Studying Aggressive NK-cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator
- Lubomir Sokol, MD, PhDMoffitt Cancer Center
- Intervention
- Siltuximab(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2024
Study locations (1)
- Moffitt Cancer Center, Tampa, Florida, United States
Collaborators
EUSA Pharma, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05316116 on ClinicalTrials.govOther trials for Aggressive NK-cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06716658JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT05863234Safety Evaluation Study for Patients With Aggressive NK-cell LeukemiaHiroshima University Hospital
- RECRUITINGPHASE2NCT05941156Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell LeukemiaThe Affiliated Hospital of Xuzhou Medical University